Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Nontuberculous Mycobacterial Infection Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The nontuberculous mycobacterial infection market has experienced steady expansion in recent years. It is anticipated to grow from $14.25 billion in 2024 to $14.96 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.0%. The historical growth of this market can be attributed to elements like improved diagnostics, an aging population, increased cystic fibrosis awareness, and the use of immunosuppressive medications.
The market size for nontuberculous mycobacterial infection is projected to experience robust expansion in the coming years, reaching “$19.37 billion by 2029 at a compound annual growth rate (CAGR) of 6.7%. This growth during the forecast period can be attributed to advancements in antimicrobial drug development, increasing NTM awareness, breakthroughs in genetic research, and the rise of telehealth and remote monitoring. Significant trends expected in the forecast period include personalized treatment, a sharper regulatory focus, the use of combination therapies, and the adoption of digital health tools.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
What Are The Drivers Pushing New Developments In The Nontuberculous Mycobacterial Infection Market?
The increasing occurrence of chronic obstructive pulmonary disease (COPD) is anticipated to fuel expansion within the nontuberculous mycobacterial infection market in the future. COPD is defined as a long-term respiratory ailment marked by ongoing and frequently worsening restriction of airflow in the lungs. Patients suffering from COPD who contract nontuberculous mycobacterial (NTM) infections experience a more pronounced reduction in forced expiratory volume in one second (FEV1) and a higher frequency of exacerbations. This condition, COPD, can compromise the immune system and harm lung tissue, thereby facilitating NTM bacteria’s ability to infect the lungs. As an illustration, a report released in March 2023 by The Scottish Public Health Observatory (ScotPHO), a public health organization based in Scotland, indicated that COPD rates started to rise between 2021 and 2022. Specifically, male rates climbed from 83.2 to 97.6 per 100,000 persons, while female rates went up from 72.6 to 97.3. Consequently, the growing incidence of chronic obstructive pulmonary disease (COPD) is a key factor propelling the expansion of the nontuberculous mycobacterial infection market.
How Is The Nontuberculous Mycobacterial Infection Market Classified Into Different Segments?
The nontuberculous mycobacterial infectionmarket covered in this report is segmented –
1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin; Clarithromycin
2) By Rifampin: Rifampin; Rifabutin
3) By Aminoglycoside: Amikacin; Streptomycin
4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid
Which Key Trends Are Expected To Influence The Nontuberculous Mycobacterial Infection Market In The Coming Years?
Major companies engaged in the nontuberculous mycobacterial infection market are adopting new treatment approval methods, such as fast track designation for drug approvals, to sustain their market position. The Fast Track designation, granted by the FDA, is a mechanism intended to accelerate the development and review of drugs targeting serious conditions where medical needs are not met. For instance, in July 2022, the Food and Drug Administration, a U.S.-based federal agency, granted Fast Track Designation to NUZYRA for treating nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is a novel broad-spectrum antibiotic developed to combat severe bacterial infections, including those from resistant strains. This designation facilitates quicker development and review processes for the NUZYRA antibiotic, thereby addressing significant unmet medical needs.
Who Are The Prominent Global Companies Shaping The Nontuberculous Mycobacterial Infection Market?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.
Download The Full Report For Exclusive Market Findings:
How Does The Nontuberculous Mycobacterial Infection Market Perform Across Key Geographic Regions?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Nontuberculous Mycobacterial Infection Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp
Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2025, By The Business Research Company
Tuberculosis Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tuberculosis-diagnostics-global-market-report
Cough And Cold Preparations Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Chronic Cough Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model